BioSpectrum the business of Bio & Health Sciences ASIA EDITION

LivsMed completes largest KOSDAQ IPO of 2025, raising Ã¢â??Â©135.9 B

January 19, 2026 | News

LivsMed will use the proceeds to build an integrated production base, fund research and development



LivsMed, a minimally invasive surgical device company, has completed an initial public offering on Korea's KOSDAQ market, raising about $94 million (Ã¢â??Â©135.9 billion) at Ã¢â??Â©55,000 per share.

Upon its debut, the company's market capitalisation surpassed Ã¢â??Â©1.4 trillion (approx. $1 billion), officially establishing its status as a premier Medtech "Unicorn." LivsMed will use the proceeds to build an integrated production base, fund research and development, and strengthen related management systems to support global growth across its product portfolio.

The offering drew significant interest from major domestic pension funds and institutions as well as large global financial institutions headquartered in New York and Boston. During institutional bookbuilding, the company reported demand of roughly 231-to-1, with overseas participation representing 8.2% of the institutional demand, including investors from the United States, the Middle East, and Asia.

LivsMed's flagship portfolio includes ArtiSential™ (launched in 2018), a line of fully articulating handheld laparoscopic instruments designed to provide wrist-like dexterity. The company has expanded its platform with ArtiSeal™, the world's only 90-degree articulating vessel sealer, enabling multi-angle access in confined anatomy.

LivsMed develops surgical solutions for minimally invasive procedures, collaborating with physicians worldwide to improve patient outcomes and expand access to advanced surgical capabilities. The company is headquartered in Seoul, Republic of Korea, and maintains a US subsidiary in San Diego, California.